## Wun-Jae Kim

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6252879/publications.pdf

Version: 2024-02-01

136885 155592 4,244 192 32 55 h-index citations g-index papers 192 192 192 6669 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Expression of hsv1-miR-H18 and hsv2-miR-H9 as a field defect marker for detecting prostate cancer. Prostate International, 2022, 10, 1-6.	1.2	5
2	Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone. Investigative and Clinical Urology, 2022, 63, 238.	1.0	3
3	Expression of RPL9 predicts the recurrence of non-muscle invasive bladder cancer with BCG therapy. Urologic Oncology: Seminars and Original Investigations, 2022, , .	0.8	2
4	In vitro and in vivo anti-tumor efficacy of krill oil against bladder cancer: Involvement of tumor-associated angiogenic vasculature. Food Research International, 2022, 156, 111144.	2.9	7
5	Induction of apoptotic cell death in human bladder cancer cells by ethanol extract of <i>Zanthoxylum schinifolium</i> leaf, through ROS-dependent inactivation of the PI3K/Akt signaling pathway. Nutrition Research and Practice, 2022, 16, 330.	0.7	3
6	TOX-expressing terminally exhausted tumor-infiltrating CD8+ T cells are reinvigorated by co-blockade of PD-1 and TIGIT in bladder cancer. Cancer Letters, 2021, 499, 137-147.	3.2	42
7	A prognostic immune predictor, HLA-DRA, plays diverse roles in non-muscle invasive and muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 237.e21-237.e29.	0.8	12
8	Prominence of urinary biomarkers for bladder cancer in the COVID-19 era: From the commercially available to new prospective candidates. Investigative and Clinical Urology, 2021, 62, 500.	1.0	4
9	Trends in End-of-Life Resource Utilization and Costs among Prostate Cancer Patients from 2006 to 2015: A Nationwide Population-Based Study. World Journal of Men?s Health, 2021, 39, 158.	1.7	6
10	A high basal metabolic rate is an independent predictor of stone recurrence in obese patients. Investigative and Clinical Urology, 2021, 62, 195.	1.0	4
11	Expression of phosphorylated p21-activated kinase 4 is associated with aggressive histologic characteristics and poor prognosis in patients with surgically treated renal cell carcinoma. Investigative and Clinical Urology, 2021, 62, 399.	1.0	2
12	A Molecular Signature Determines the Prognostic and Therapeutic Subtype of Non-Muscle-Invasive Bladder Cancer Responsive to Intravesical Bacillus Calmette-Guérin Therapy. International Journal of Molecular Sciences, 2021, 22, 1450.	1.8	6
13	Role of Exosomal miRNA in Bladder Cancer: A Promising Liquid Biopsy Biomarker. International Journal of Molecular Sciences, 2021, 22, 1713.	1.8	36
14	Betulinic Acid Restricts Human Bladder Cancer Cell Proliferation In Vitro by Inducing Caspase-Dependent Cell Death and Cell Cycle Arrest, and Decreasing Metastatic Potential. Molecules, 2021, 26, 1381.	1.7	15
15	Collagen typeÂVlâ€Î±1 and 2 repress the proliferation, migration and invasion of bladder cancer cells. International Journal of Oncology, 2021, 59, .	1.4	21
16	Effect of pre-operative internal obturator muscle mass index in MRI on biochemical recurrence of prostate cancer patients after radical prostatectomy: a multi-center study. BMC Urology, 2021, 21, 85.	0.6	1
17	A Novel Cyclic Pentadepsipeptide, N-Methylsansalvamide, Suppresses Angiogenic Responses and Exhibits Antitumor Efficacy against Bladder Cancer. Cancers, 2021, 13, 191.	1.7	6
18	Urinary microRNA-1913 to microRNA-3659 expression ratio as a non-invasive diagnostic biomarker for prostate cancer. Investigative and Clinical Urology, 2021, 62, 340.	1.0	14

#	Article	IF	CITATIONS
19	Nutritional status assessed by the Controlling Nutritional Status (CONUT) score as a predictor of recurrence of urolithiasis. Investigative and Clinical Urology, 2021, 62, 553.	1.0	2
20	The prognostic value of the pretreatment serum albumin to globulin ratio for predicting adverse pathology in patients undergoing radical prostatectomy for prostate cancer. Investigative and Clinical Urology, 2021, 62, 545.	1.0	6
21	A Low Geriatric Nutritional Risk Index is Associated with Aggressive Pathologic Characteristics and Poor Survival after Nephrectomy in Clear Renal Cell Carcinoma: A Multicenter Retrospective Study. Nutrition and Cancer, 2020, 72, 88-97.	0.9	19
22	The age-adjusted Charlson comorbidity index as a predictor of overall survival of surgically treated non-metastatic clear cell renal cell carcinoma. Journal of Cancer Research and Clinical Oncology, 2020, 146, 187-196.	1.2	24
23	Negative Effect of Reduced NME1 Expression on Recurrence-Free Survival in Early Stage Non-Small Cell Lung Cancer. Journal of Clinical Medicine, 2020, 9, 3067.	1.0	4
24	In Vitro and In Vivo Antitumor Efficacy of Hizikia fusiforme Celluclast Extract against Bladder Cancer. Nutrients, 2020, 12, 2159.	1.7	6
25	Induction of Apoptosis by Coptisine in Hep3B Hepatocellular Carcinoma Cells through Activation of the ROS-Mediated JNK Signaling Pathway. International Journal of Molecular Sciences, 2020, 21, 5502.	1.8	15
26	The immunostimulatory effect of indole-6-carboxaldehyde isolated from <i>Sargassum thunbergii</i> <b>(Mertens) Kuntze</b> in RAW 264.7 macrophages. Animal Cells and Systems, 2020, 24, 233-241.	0.8	6
27	Carnosine Impedes PDGF-Stimulated Proliferation and Migration of Vascular Smooth Muscle Cells In Vitro and Sprout Outgrowth Ex Vivo. Nutrients, 2020, 12, 2697.	1.7	4
28	Evaluation of the In Vitro and In Vivo Antitumor Efficacy of Peanut Sprout Extracts Cultivated with Fermented Sawdust Medium Against Bladder Cancer. Applied Sciences (Switzerland), 2020, 10, 8758.	1.3	3
29	Honokiol ameliorates oxidative stress-induced DNA damage and apoptosis of c2c12 myoblasts by ROS generation and mitochondrial pathway. Animal Cells and Systems, 2020, 24, 60-68.	0.8	18
30	Tumor heterogeneity in muscle-invasive bladder cancer. Translational Andrology and Urology, 2020, 9, 2866-2880.	0.6	11
31	Advances in urinary biomarker discovery in urological research. Investigative and Clinical Urology, 2020, 61, S8.	1.0	22
32	Peanut Sprout Extracts Cultivated with Fermented Sawdust Medium Inhibits Benign Prostatic Hyperplasia <i>In Vitro</i> and <i>In Vivo</i> World Journal of Men?s Health, 2020, 38, 385.	1.7	12
33	A novel tumor suppressing gene, ARHGAP9, is an independent prognostic biomarker for bladder cancer. Oncology Letters, 2020, 19, 476-486.	0.8	9
34	Proteomic profiling of bladder cancer for precision medicine in the clinical setting: A review for the busy urologist. Investigative and Clinical Urology, 2020, 61, 539.	1.0	3
35	A novel urinary mRNA signature using the droplet digital polymerase chain reaction platform improves discrimination between prostate cancer and benign prostatic hyperplasia within the prostate-specific antigen gray zone. Investigative and Clinical Urology, 2020, 61, 411.	1.0	7
36	Utilizing machine learning to discern hidden clinical values from big data in urology. Investigative and Clinical Urology, 2020, 61, 239.	1.0	0

#	Article	IF	CITATIONS
37	The therapeutic and prognostic implications of molecular biomarkers in urothelial carcinoma. Translational Cancer Research, 2020, 9, 6609-6623.	0.4	1
38	Nimbolide Represses the Proliferation, Migration, and Invasion of Bladder Carcinoma Cells via Chk2-Mediated G2/M Phase Cell Cycle Arrest, Altered Signaling Pathways, and Reduced Transcription Factors-Associated MMP-9 Expression. Evidence-based Complementary and Alternative Medicine, 2019, 2019, 1-12.	0.5	14
39	Anti-Proliferative and Pro-Apoptotic Effects of Licochalcone A through ROS-Mediated Cell Cycle Arrest and Apoptosis in Human Bladder Cancer Cells. International Journal of Molecular Sciences, 2019, 20, 3820.	1.8	46
40	Triacanthine exerts antitumor effects on bladder cancer in vitro and in vivo. Phytomedicine, 2019, 64, 153069.	2.3	22
41	For Physicians Managing Voiding Dysfunction, Improving the Detection Rate of Early Prostate Cancer and Discrimination From Benign Prostatic Hyperplasia, in a Molecular Biomarker Aspects. International Neurourology Journal, 2019, 23, 5-12.	0.5	6
42	Isorhamnetin Induces Cell Cycle Arrest and Apoptosis Via Reactive Oxygen Species-Mediated AMP-Activated Protein Kinase Signaling Pathway Activation in Human Bladder Cancer Cells. Cancers, 2019, 11, 1494.	1.7	33
43	Citrus unshiu peel suppress the metastatic potential of murine melanoma B16F10 cells in vitro and in vivo. Phytotherapy Research, 2019, 33, 3228-3241.	2.8	8
44	Necrotizing fasciitis associated with sorafenib treatment. IDCases, 2019, 18, e00611.	0.4	4
45	Carnosine exerts antitumor activity against bladder cancers in vitro and in vivo via suppression of angiogenesis. Journal of Nutritional Biochemistry, 2019, 74, 108230.	1.9	10
46	National practice patterns and direct medical costs for prostate cancer in Korea across a 10 year period: a nationwide population-based study using a national health insurance database. BMC Health Services Research, 2019, 19, 408.	0.9	11
47	Protective effect of diphlorethohydroxycarmalol against oxidative stress-induced DNA damage and apoptosis in retinal pigment epithelial cells. Cutaneous and Ocular Toxicology, 2019, 38, 298-308.	0.5	20
48	Twenty-four-hour urine osmolality as a representative index of adequate hydration and a predictor of recurrence in patients with urolithiasis. International Urology and Nephrology, 2019, 51, 1129-1135.	0.6	8
49	Urinary Cell-Free DNA IQGAP3/BMP4 Ratio as a Prognostic Marker for Non–Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer, 2019, 17, e704-e711.	0.9	12
50	Hydrangenol suppresses VEGF-stimulated angiogenesis by targeting p27KIP1-dependent G1-cell cycle arrest, VEGFR-2-mediated signaling, and MMP-2 expression. Animal Cells and Systems, 2019, 23, 72-81.	0.8	14
51	Innovative technologies for the smart E-Healthcare system. Investigative and Clinical Urology, 2019, 60, 1.	1.0	1
52	ZNF492 and GPR149 methylation patterns as prognostic markers for clear cell renal cell carcinoma: Arrayâ€'based DNA methylation profiling. Oncology Reports, 2019, 42, 453-460.	1,2	6
53	Urinary cellâ€free microRNA biomarker could discriminate bladder cancer from benign hematuria. International Journal of Cancer, 2019, 144, 380-388.	2.3	30
54	Diagnostic value of combined IQGAP3/BMP4 and IQGAP3/FAM107A expression ratios in urinary cell-free DNA for discriminating bladder cancer from hematuria. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 86-96.	0.8	11

#	Article	IF	Citations
55	Morphological Assessment of Apoptosis Induced by Nimbolide; A Limonoid from. Iranian Journal of Pharmaceutical Research, 2019, 18, 846-859.	0.3	7
56	Methylation Signature for Prediction of Progression Free Survival in Surgically Treated Clear Cell Renal Cell Carcinoma. Journal of Korean Medical Science, 2019, 34, e144.	1.1	17
57	Medical Travel among Non-Seoul Residents to Seek Prostate Cancer Treatment in Medical Facilities of Seoul. Cancer Research and Treatment, 2019, 51, 53-64.	1.3	10
58	Trends in clinical, operative, and pathologic characteristics of surgically treated renal mass in a Korean center: A surgical series from 1988 through 2015. Investigative and Clinical Urology, 2019, 60, 184.	1.0	2
59	Predictive Molecular and Protein Markers for the Recurrence of Nonmuscle Invasive Bladder Cancer. The Korean Journal of Urological Oncology, 2019, 17, 81-87.	0.1	0
60	Molecular Progression Risk Score for Prediction of Muscle Invasion in Primary T1 High-Grade Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, 274-280.	0.9	8
61	Urinary cell-free nucleic acid IQGAP3: a new non-invasive diagnostic marker for bladder cancer. Oncotarget, 2018, 9, 14354-14365.	0.8	30
62	<i>CDC6</i> mRNA Expression Is Associated with the Aggressiveness of Prostate Cancer. Journal of Korean Medical Science, 2018, 33, e303.	1.1	19
63	Clinical, prognostic, and therapeutic significance of heat shock protein 27 in bladder cancer. Oncotarget, 2018, 9, 7961-7974.	0.8	9
64	Prognostic Impact of Nutritional Status Assessed by the Controlling Nutritional Status (CONUT) Score in Patients with Surgically Treated Renal Cell Carcinoma. Nutrition and Cancer, 2018, 70, 886-894.	0.9	18
65	Knowledge-based diagnosis and prediction using big data and deep learning in precision medicine. Investigative and Clinical Urology, 2018, 59, 69.	1.0	6
66	The p21-activated kinase 4-Slug transcription factor axis promotes epithelialâ- mesenchymal transition and worsens prognosis in prostate cancer. Oncogene, 2018, 37, 5147-5159.	2.6	41
67	Inhibitory effect of Au@Pt-NSs on proliferation, migration, and invasion of EJ bladder carcinoma cells: involvement of cell cycle regulators, signaling pathways, and transcription factor-mediated MMP-9 expression. International Journal of Nanomedicine, 2018, Volume 13, 3295-3310.	3.3	7
68	Unmasking molecular profiles of bladder cancer. Investigative and Clinical Urology, 2018, 59, 72.	1.0	23
69	Hydrangenol inhibits the proliferation, migration, and invasion of EJ bladder cancer cells via p21-mediated G1-phase cell cycle arrest, p38 MAPK activation, and reduction in Sp-1-induced MMP-9 expression. EXCLI Journal, 2018, 17, 531-543.	0.5	9
70	Identification of differentially expressed miRNAs and miRNA-targeted genes in bladder cancer. Oncotarget, 2018, 9, 27656-27666.	0.8	20
71	The Role of MicroRNAs in Oncogenesis and Progression of Prostate Cancer. The Korean Journal of Urological Oncology, 2018, 16, 1-6.	0.1	1
72	Generation of Whole-Genome Sequencing Data for Comparing Primary and Castration-Resistant Prostate Cancer. Genomics and Informatics, 2018, 16, 71-74.	0.4	1

#	Article	IF	CITATIONS
73	Precision Medicine in Castration-Resistant Prostate Cancer. The Korean Journal of Urological Oncology, 2018, 16, 97-102.	0.1	0
74	Antioxidant and cytoprotective effects of morin against hydrogen peroxide-induced oxidative stress are associated with the induction of Nrf-2-mediated HO-1 expression in V79-4 Chinese hamster lung fibroblasts. International Journal of Molecular Medicine, 2017, 39, 672-680.	1.8	37
<b>7</b> 5	Metabolic Characteristics and Risks Associated with Stone Recurrence in Korean Young Adult Stone Patients. Journal of Endourology, 2017, 31, 806-811.	1.1	7
76	Looking to the metabolic landscapes for prostate health monitoring. Prostate International, 2017, 5, 85-88.	1.2	7
77	Evaluation of the Immune Responses to and Cross-Protective Efficacy of Eurasian H7 Avian Influenza Viruses. Journal of Virology, 2017, 91, .	1.5	10
78	HSP70-1 is required for interleukin-5-induced angiogenic responses through eNOS pathway. Scientific Reports, 2017, 7, 44687.	1.6	30
79	Morin Inhibits Proliferation, Migration, and Invasion of Bladder Cancer EJ Cells via Modulation of Signaling Pathways, Cell Cycle Regulators, and Transcription Factorâ€Mediated MMPâ€9 Expression. Drug Development Research, 2017, 78, 81-90.	1.4	25
80	Kinesin Family Member 11 mRNA Expression Predicts Prostate Cancer Aggressiveness. Clinical Genitourinary Cancer, 2017, 15, 450-454.	0.9	14
81	Expression levels of FGFR3 as a prognostic marker for the progression of primary pT1 bladder cancer and its association with mutation status. Oncology Letters, 2017, 14, 3817-3824.	0.8	29
82	Change in Prostate Specific Antigen Concentration in Men with Prostate Specific Antigen Less than 2.5 ng/ml Taking Low Dose Finasteride or Dutasteride for Male Androgenetic Alopecia. Journal of Urology, 2017, 198, 1340-1345.	0.2	2
83	Long-term validation of a molecular progression-associated gene classifier for prediction of muscle invasion in primary non-muscle-invasive bladder cancer. Oncology Letters, 2017, 14, 2468-2474.	0.8	6
84	Angiopoietin-like protein 4 potentiates DATS-induced inhibition of proliferation, migration, and invasion of bladder cancer EJ cells; involvement of G <sub>2</sub> /M-phase cell cycle arrest, signaling pathways, and transcription factors-mediated MMP-9 expression. Food and Nutrition Research, 2017, 61, 1338918.	1.2	8
85	Fucoidan Induces ROSâ€Dependent Apoptosis in 5637 Human Bladder Cancer Cells by Downregulating Telomerase Activity via Inactivation of the PI3K/Akt Signaling Pathway. Drug Development Research, 2017, 78, 37-48.	1.4	42
86	Ethanol extract of loquat fruit skin inhibits the proliferation and metastatic potential of EJ human bladder carcinoma cells. Animal Cells and Systems, 2017, 21, 323-331.	0.8	0
87	Chronological Trends in Clinical and Urinary Metabolic Features over 20 Years in Korean Urolithiasis Patients. Journal of Korean Medical Science, 2017, 32, 1496.	1.1	7
88	The Author's Response: ASA Physical Status Classification in Surgical Oncology and the Importance of Improving Inter-Rater Reliability. Journal of Korean Medical Science, 2017, 32, 1213.	1.1	0
89	HSPA6 augments garlic extract-induced inhibition of proliferation, migration, and invasion of bladder cancer EJ cells; Implication for cell cycle dysregulation, signaling pathway alteration, and transcription factor-associated MMP-9 regulation. PLoS ONE, 2017, 12, e0171860.	1.1	39
90	Impact of the ASA Physical Status Score on Adjuvant Chemotherapy Eligibility and Survival of Upper Tract Urothelial Carcinoma Patients: a Multicenter Study. Journal of Korean Medical Science, 2017, 32, 335.	1.1	10

#	Article	IF	Citations
91	Impact of a bladder cuff excision during radical nephroureterectomy on cancer specific survival in patients with upper tract urothelial cancer in Korea: a retrospective, multi-institutional study. Minerva Urology and Nephrology, 2017, 69, 466-474.	1.3	7
92	Baicalein Inhibits the Migration and Invasion of B16F10 Mouse Melanoma Cells through Inactivation of the PI3K/Akt Signaling Pathway. Biomolecules and Therapeutics, 2017, 25, 213-221.	1.1	36
93	MicroRNA-892b influences proliferation, migration and invasion of bladder cancer cells by mediating the p19ARF/cyclin D1/CDK6 and Sp-1/MMP-9 pathways. Oncology Reports, 2016, 36, 2313-2320.	1.2	25
94	A Prospective Multicenter Trial of the Efficacy and Tolerability of Neoadjuvant Sunitinib for Inoperable Metastatic Renal Cell Carcinoma. Journal of Korean Medical Science, 2016, 31, 1983.	1.1	3
95	Can lymphovascular invasion replace the prognostic value of lymph node involvement in patients with upper tract urothelial carcinoma after radical nephroureterectomy?. Canadian Urological Association Journal, 2016, 10, 229.	0.3	1
96	Changing landscape of diagnosis and treatment of bladder cancer. Investigative and Clinical Urology, 2016, 57, S1.	1.0	3
97	How do we manage high-grade T1 bladder cancer? Conservative or aggressive therapy?. Investigative and Clinical Urology, 2016, 57, S44.	1.0	19
98	Impact of Young Age at Diagnosis on Survival in Patients with Surgically Treated Renal Cell Carcinoma: a Multicenter Study. Journal of Korean Medical Science, 2016, 31, 1976.	1.1	20
99	Can we use methylation markers as diagnostic and prognostic indicators for bladder cancer?. Investigative and Clinical Urology, 2016, 57, S77.	1.0	18
100	RSPH9 methylation pattern as a prognostic indicator in patients with non-muscle invasive bladder cancer. Oncology Reports, 2016, 35, 1195-1203.	1.2	11
101	MicroRNA-106a suppresses proliferation, migration, and invasion of bladder cancer cells by modulating MAPK signaling cell cycle regulators, and Ets-1-mediated MMP-2 expression. Oncology Reports, 2016, 36, 2421-2429.	1.2	27
102	Sanguinarine Induces Apoptosis of Human Oral Squamous Cell Carcinoma KB Cells via Inactivation of the PI3K/Akt Signaling Pathway. Drug Development Research, 2016, 77, 227-240.	1.4	17
103	Esculetin Inhibits VEGF-Induced Angiogenesis Both <i>In Vitro</i> li>and <i>In Vivo</i> . The American Journal of Chinese Medicine, 2016, 44, 61-76.	1.5	29
104	Rosa hybrida extract suppresses vascular smooth muscle cell responses by the targeting of signaling pathways, cell cycle regulation and matrix metalloproteinase-9 expression. International Journal of Molecular Medicine, 2016, 37, 1119-1126.	1.8	7
105	UBE2C cell-free RNA in urine can discriminate between bladder cancer and hematuria. Oncotarget, 2016, 7, 58193-58202.	0.8	35
106	Increased Expression of Herpes Virus-Encoded hsv1-miR-H18 and hsv2-miR-H9-5p in Cancer-Containing Prostate Tissue Compared to That in Benign Prostate Hyperplasia Tissue. International Neurourology Journal, 2016, 20, 122-130.	0.5	12
107	Virus encoded circulatory miRNAs for early detection of prostate cancer. BMC Urology, 2015, 15, 116.	0.6	3
108	Preoperative Underweight Patients with Upper Tract Urothelial Carcinoma Survive Less after Radical Nephroureterectomy. Journal of Korean Medical Science, 2015, 30, 1483.	1.1	16

#	Article	IF	CITATIONS
109	Urinary Nucleic Acid <i>TSPAN13</i> -to- <i>S100A9</i> Ratio as a Diagnostic Marker in Prostate Cancer. Journal of Korean Medical Science, 2015, 30, 1784.	1.1	7
110	Lower Levels of Human MOB3B Are Associated with Prostate Cancer Susceptibility and Aggressive Clinicopathological Characteristics. Journal of Korean Medical Science, 2015, 30, 937.	1.1	8
111	The c-MET Network as Novel Prognostic Marker for Predicting Bladder Cancer Patients with an Increased Risk of Developing Aggressive Disease. PLoS ONE, 2015, 10, e0134552.	1.1	14
112	p21WAF1 Is Required for Interleukin-16-Induced Migration and Invasion of Vascular Smooth Muscle Cells via the p38MAPK/Sp-1/MMP-9 Pathway. PLoS ONE, 2015, 10, e0142153.	1.1	23
113	Clinical Implications and Prognostic Values of <i>Prostate Cancer Susceptibility Candidate &lt; /i&gt;Methylation in Primary Nonmuscle Invasive Bladder Cancer. Disease Markers, 2015, 2015, 1-6.</i>	0.6	8
114	Is 5´-AMP-Activated Protein Kinase Both Jekyll and Hyde in Bladder Cancer?. International Neurourology Journal, 2015, 19, 55-66.	0.5	7
115	Luteolin acts as a radiosensitizer in non-small cell lung cancer cells by enhancing apoptotic cell death through activation of a p38/ROS/caspase cascade. International Journal of Oncology, 2015, 46, 1149-1158.	1.4	49
116	MicroRNA-20b inhibits the proliferation, migration and invasion of bladder cancer EJ cells via the targeting of cell cycle regulation and Sp-1-mediated MMP-2 expression. Oncology Reports, 2015, 34, 1605-1612.	1.2	35
117	Anti-inflammatory potential of saponins derived from cultured wild ginseng roots in lipopolysaccharide-stimulated RAW 264.7 macrophages. International Journal of Molecular Medicine, 2015, 35, 1690-1698.	1.8	22
118	Podophyllotoxin acetate enhances $\hat{l}^3$ -ionizing radiation-induced apoptotic cell death by stimulating the ROS/p38/caspase pathway. Biomedicine and Pharmacotherapy, 2015, 70, 111-118.	2.5	31
119	Melittin has a chondroprotective effect by inhibiting MMP-1 and MMP-8 expressions via blocking NF-κB and AP-1 signaling pathway in chondrocytes. International Immunopharmacology, 2015, 25, 400-405.	1.7	32
120	Comparison of mRNA, Protein, and Urinary Nucleic Acid Levels of S100A8 and S100A9 between Prostate Cancer and BPH. Annals of Surgical Oncology, 2015, 22, 2439-2445.	0.7	15
121	Antagonistic effects of acetylshikonin on LPS-induced NO and PGE2 production in BV2 microglial cells via inhibition of ROS/PI3K/Akt-mediated NF-ήB signaling and activation of Nrf2-dependent HO-1. In Vitro Cellular and Developmental Biology - Animal, 2015, 51, 975-986.	0.7	10
122	Activation of <i>EZH2</i> and <i>SUZ12</i> Regulated by E2F1 Predicts the Disease Progression and Aggressive Characteristics of Bladder Cancer. Clinical Cancer Research, 2015, 21, 5391-5403.	3.2	103
123	Prognostic Significance of CREB-Binding Protein and CD81 Expression in Primary High Grade Non-Muscle Invasive Bladder Cancer: Identification of Novel Biomarkers for Bladder Cancer Using Antibody Microarray. PLoS ONE, 2015, 10, e0125405.	1.1	18
124	Overexpression of caldesmon is associated with tumor progression in patients with primary non-muscle-invasive bladder cancer. Oncotarget, 2015, 6, 40370-40384.	0.8	20
125	The Histone Deacetylase Inhibitor Trichostatin A Sensitizes Human Renal Carcinoma Cells to TRAIL-Induced Apoptosis through Down-Regulation of c-FLIPL. Biomolecules and Therapeutics, 2015, 23, 31-38.	1.1	14
126	Urinary MicroRNAs of Prostate Cancer: Virus-Encoded hsv1-miRH18 and hsv2-miR-H9-5p Could Be Valuable Diagnostic Markers. International Neurourology Journal, 2015, 19, 74-84.	0.5	40

#	Article	IF	Citations
127	Effects of Previous or Synchronous Non-Muscle Invasive Bladder Cancer on Clinical Results after Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Multi-Institutional Study. Urology Journal, 2015, 12, 2233-9.	0.3	9
128	Anti-Inflammatory Potential of Newly Synthesized 4-[(Butylsulfinyl)methyl]-1,2-benzenediol in Lipopolysaccharide-Stimulated BV2 Microglia. Molecules, 2014, 19, 16609-16623.	1.7	5
129	Role of 1,25-Dihydroxy Vitamin D <sub>3</sub> and Parathyroid Hormone in Urinary Calcium Excretion in Calcium Stone Formers. Yonsei Medical Journal, 2014, 55, 1326.	0.9	13
130	Effect of Renal Insufficiency on Stone Recurrence in Patients with Urolithiasis. Journal of Korean Medical Science, 2014, 29, 1132.	1.1	13
131	Diagnosis of bladder cancer and prediction of survival by urinary metabolomics. Oncotarget, 2014, 5, 1635-1645.	0.8	130
132	Novel Combination Markers for Predicting Survival in Patients with Muscle Invasive Bladder Cancer: USP18 and DGCR2. Journal of Korean Medical Science, 2014, 29, 351.	1.1	29
133	Nuclear and cytoplasmic p53 suppress cell invasion by inhibiting respiratory Complex-I activity via BcI-2 family proteins. Oncotarget, 2014, 5, 8452-8465.	0.8	44
134	Expression of Human Endogenous Retrovirus env Genes in the Blood of Breast Cancer Patients. International Journal of Molecular Sciences, 2014, 15, 9173-9183.	1.8	48
135	Cooperative actions of p21 <scp><sup>WAF</sup></scp> <sup>1</sup> and p53 induce Slug protein degradation and suppress cell invasion. EMBO Reports, 2014, 15, 1062-1068.	2.0	65
136	Decreased selenium-binding protein 1 mRNA expression is associated with poor prognosis in renal cell carcinoma. World Journal of Surgical Oncology, 2014, 12, 288.	0.8	18
137	Expression Signature Defined by <i>FOXM1–CCNB1</i> Activation Predicts Disease Recurrence in Non–Muscle-Invasive Bladder Cancer. Clinical Cancer Research, 2014, 20, 3233-3243.	3.2	50
138	Impact of Transobturator Tape Treatment on Overactive Bladder Symptoms, Particularly Nocturia, in Patients With Mixed Urinary Incontinence. Korean Journal of Urology, 2014, 55, 520.	1.2	3
139	Distinct Metabolic Characteristics and Risk of Stone Recurrence in Patients With Multiple Stones at the First-time Presentation. Urology, 2014, 84, 274-278.	0.5	4
140	The predictive value of GSTT1 polymorphisms in predicting the early response to induction BCG therapy in patients with non–muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 458-465.	0.8	9
141	Tianeptine sodium salt suppresses TNF-α-induced expression of matrix metalloproteinase-9 in human carcinoma cells via suppression of the Pl3K/Akt-mediated NF-ΰB pathway. Environmental Toxicology and Pharmacology, 2014, 38, 502-509.	2.0	5
142	p21WAF1 mediates the IL-15-induced migration and invasion of human bladder cancer 5637 cells via the ERK1/2/NF-κB/MMP-9 pathway. International Immunopharmacology, 2014, 22, 59-65.	1.7	14
143	APPEX: analysis platform for the identification of prognostic gene expression signatures in cancer. Bioinformatics, 2014, 30, 3284-3286.	1.8	10
144	Hypertriglyceridemia Is Associated With Increased Risk for Stone Recurrence in Patients With Urolithiasis. Urology, 2014, 84, 766-771.	0.5	21

#	Article	IF	CITATIONS
145	p27KIP1 is involved in ERK1/2-mediated MMP-9 expression via the activation of NF-κB binding in the IL-7-induced migration and invasion of 5637 cells. International Journal of Oncology, 2014, 44, 1349-1356.	1.4	27
146	EPO gene expression induces the proliferation, migration and invasion of bladder cancer cells through the p21WAF1-mediated ERK1/2/NF-βB/MMP-9 pathway. Oncology Reports, 2014, 32, 2207-2214.	1.2	11
147	Comparative proteome analysis of Tumor necrosis factor $\hat{l}\pm$ -stimulated human Vascular Smooth Muscle Cells in response to melittin. Proteome Science, 2013, 11, 20.	0.7	8
148	Interleukin-5 enhances the migration and invasion of bladder cancer cells via ERK1/2-mediated MMP-9/NF-κB/AP-1 pathway: Involvement of the p21WAF1 expression. Cellular Signalling, 2013, 25, 2025-2038.	1.7	62
149	<i>HOXA9</i> , <i>ISL1</i> and <i>ALDH1A3</i> methylation patterns as prognostic markers for nonmuscle invasive bladder cancer: Arrayâ€based DNA methylation and expression profiling. International Journal of Cancer, 2013, 133, 1135-1142.	2.3	100
150	Investigational cell cycle inhibitors in clinical trials for bladder cancer. Expert Opinion on Investigational Drugs, 2013, 22, 369-377.	1.9	13
151	MicroRNAs in prostate cancer. Prostate International, 2013, 1, 3-9.	1.2	57
152	Cell-Free microRNA-214 From Urine as a Biomarker for Non-Muscle-Invasive Bladder Cancer. Korean Journal of Urology, 2013, 54, 791.	1.2	59
153	Decreased (i>DBC1 (i>Expression Is Associated With Poor Prognosis in Patients With Non-Muscle-Invasive Bladder Cancer. Korean Journal of Urology, 2013, 54, 631.	1.2	8
154	The TREK2 Channel Is Involved in the Proliferation of 253J Cell, a Human Bladder Carcinoma Cell. Korean Journal of Physiology and Pharmacology, 2013, 17, 511.	0.6	13
155	Interleukin-20 Promotes Migration of Bladder Cancer Cells through Extracellular Signal-regulated Kinase (ERK)-mediated MMP-9 Protein Expression Leading to Nuclear Factor (NF-κB) Activation by Inducing the Up-regulation of p21WAF1 Protein Expression *. Journal of Biological Chemistry, 2013, 288, 5539-5552.	1.6	81
156	Locally recurrent penile apocrine carcinoma initially diagnosed as metastatic adenocarcinoma of colon. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2013, 25, 777-80.	0.7	1
157	Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer. International Journal of Oncology, 2012, 41, 1871-1878.	1.4	134
158	Epigenetics of Bladder Cancer. Methods in Molecular Biology, 2012, 863, 111-118.	0.4	11
159	FAM70Bas a Novel Prognostic Marker for Cancer Progression and Cancer-Specific Death in Muscle-Invasive Bladder Cancer. Korean Journal of Urology, 2012, 53, 598.	1.2	8
160	HMOX1 is an Important Prognostic Indicator of Nonmuscle Invasive Bladder Cancer Recurrence and Progression. Journal of Urology, 2011, 185, 701-705.	0.2	48
161	A Four-Gene Signature Predicts Disease Progression in Muscle Invasive Bladder Cancer. Molecular Medicine, 2011, 17, 478-485.	1.9	60
162	<i>GSTM1</i> Tissue Genotype as a Recurrence Predictor in Non-muscle Invasive Bladder Cancer. Journal of Korean Medical Science, 2011, 26, 231.	1.1	15

#	Article	IF	Citations
163	Variants of BORIS minisatellites and relation to prognosis of prostate cancer. Genes and Genomics, 2011, 33, 49-56.	0.5	4
164	<i>EFEMP1</i> as a Novel DNA Methylation Marker for Prostate Cancer: Array-Based DNA Methylation and Expression Profiling. Clinical Cancer Research, 2011, 17, 4523-4530.	3.2	61
165	<i>GSTT1</i> as a Prognosticator for Recurrence and Progression in Patients with Non-Muscle-Invasive Bladder Cancer. Disease Markers, 2010, 29, 81-87.	0.6	11
166	Expression Signature of <i>E2F1</i> and Its Associated Genes Predict Superficial to Invasive Progression of Bladder Tumors. Journal of Clinical Oncology, 2010, 28, 2660-2667.	0.8	296
167	Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Molecular Cancer, 2010, 9, 3.	7.9	309
168	Task manifestation-based clinical protocol specification for ubiquitous healthcare services., 2010,,.		0
169	Can We Use Single Nucleotide Polymorphism and Runt Domain Transcription Factor 3 Methylation as Tumor Markers for Bladder Cancer?. Korean Journal of Urology, 2009, 50, 311.	1.2	1
170	Using Emerging Subsequence in Classifying Protein Structural Class. , 2009, , .		2
171	Changes in Urinary Lithogenic Features Over Time in Patients With Urolithiasis. Urology, 2009, 74, 51-55.	0.5	8
172	Epigenetic biomarkers in urothelial bladder cancer. Expert Review of Molecular Diagnostics, 2009, 9, 259-269.	1.5	34
173	The Relationship between RUNX3 Inactivation and Its Pathological Features in Renal Cell Carcinoma. Korean Journal of Urology, 2009, 50, 432.	1.2	2
174	SSL1 åºSé•·ã®ã"ã•ãº(ç∙뼚特å^¥ã,∙ãf³ãƒã,ã,¦ãƒ1「ã,¢ã,ã,¢å᠈½éš›å±åŒç"ç©¶ã®ç¾çжã•展望〕第′	97 <b>åxž</b> æ—¥	æooc¬æ³Œå°
175	Molecular biomarkers in urothelial bladder cancer. Cancer Science, 2008, 99, 646-652.	1.7	113
176	Impact of Obesity in Patients With Urolithiasis and its Prognostic Usefulness in Stone Recurrence. Journal of Urology, 2008, 179, 570-574.	0.2	84
177	Analysis of the Expression of Peroxiredoxin I in Human Bladder Cancer. Korean Journal of Urology, 2008, 49, 300.	0.2	0
178	Utility of Smo as a Prognostic Marker for Human Bladder Tumors. Korean Journal of Urology, 2007, 48, 997.	0.2	4
179	Efficacy of Standard Diet Therapy for Patients with Urolithiasis. Korean Journal of Urology, 2007, 48, 608.	0.2	1
180	The Expression and Clinical Implications of Forkhead Trasnscription Factor FKHR (FOXO1) in Human Bladder Cancer. Korean Journal of Urology, 2007, 48, 396.	0.2	0

#	Article	IF	Citations
181	Biomarkers in bladder cancer: present status and perspectives. Biomarker Insights, 2007, 2, 95-105.	1.0	3
182	Epigenetic markers for bladder cancer in urine. Translational Oncogenomics, 2007, 2, 35-42.	1.7	1
183	The Distant Management System of BPH Patients using the Tele-communications. Korean Journal of Urology, 2006, 47, 489.	0.2	2
184	Korean Nomogram for the Prediction of Recurrence-free Survival after Definitive Surgery for Renal Cell Carcinoma. Korean Journal of Urology, 2006, 47, 963.	0.2	0
185	Effects of Transforming Growth Factor- $\hat{l}^21$ and Its Receptor on the Development, Recurrence and Progression of Human Bladder Cancer. Korean Journal of Urology, 2006, 47, 426.	0.2	2
186	Local Effects of Antimuscarinics on Muscarinic Receptors in Bladder Sensory Nerves. Journal of the Korean Continence Society, 2006, 10, 17.	0.1	0
187	Genetic and epigenetic aspects of bladder cancer. Journal of Cellular Biochemistry, 2005, 95, 24-33.	1.2	19
188	RUNX3 Inactivation by Point Mutations and Aberrant DNA Methylation in Bladder Tumors. Cancer Research, 2005, 65, 9347-9354.	0.4	142
189	å‰ç«‹è…ºãŒã,"æ,£è€…ã«ãŠã⁵ã,‹è¡€ä¸å§è±†ã,¤,½ãƒ•ãƒ©ãƒœãƒ³ã®ææè°Ž∶日韓米ã®ç—‡ä¾‹å⁻¾ç…§ç"ç	: <b>©Ф(0</b> 7¬9:	3å <b>ૹ</b> æ—¥æœ
190	COLLAGEN-TO-SMOOTH MUSCLE RATIO HELPS PREDICTION OF PROGNOSIS AFTER PYELOPLASTY. Journal of Urology, 2000, 163, 1271-1275.	0.2	37
191	Multifactorial Involvement of Multidrug Resistance Protein, DNA Topoisomerase II and Glutathione/Glutathione-S-Transferase in NonP- Glycoprotein-Mediated Multidrug Resistance in Human Bladder Cancer Cells. International Journal of Urology, 1997, 4, 583-590.	0.5	15
192	Multidrug Resistance-associated Protein-mediated Multidrug Resistance Modulated by Cyclosporin A in a Human Bladder Cancer Cell Line. Japanese Journal of Cancer Research, 1995, 86, 969-977.	1.7	24